Nykode Therapeutics AS (OTCMKTS:VACBF) Short Interest Update

Nykode Therapeutics AS (OTCMKTS:VACBF) saw a significant decrease in short interest in the month of March. As of March 31st, there was short interest totaling 329,150 shares, a decrease of 55.7% from the March 15th total of 743,685 shares. Based on an average trading volume of 0 shares, the days-to-cover ratio is currently ∞ days.

Nykode Therapeutics AS Stock Performance

Nykode Therapeutics AS stock opened at $0.38 on Friday. Nykode Therapeutics AS has a 52-week low of $0.16 and a 52-week high of $0.38. The business has a 50-day simple moving average of $0.37 and a two-hundred day simple moving average of $0.26.

About Nykode Therapeutics AS

Nykode Therapeutics AS (OTCMKTS:VACBF) is a clinical-stage biotechnology company based in Oslo, Norway, focused on the development of precisely targeted immunotherapies. The company’s proprietary platform is designed to deliver antigenic payloads directly to antigen-presenting cells, with the goal of eliciting potent and durable immune responses against both cancerous and infectious disease targets. By combining modular antigen design with novel delivery modalities, Nykode aims to drive next-generation vaccine and immunotherapy solutions.

The company’s clinical pipeline includes several lead candidates in oncology and infectious diseases.